IMS Health executive: Generic competition can help U.S. save billions

NEW YORK Loss of patent protection for branded drugs and subsequent competition from generics could save the U.S. healthcare system $70 billion or more over the next four years, according to published reports.


Reuters reported IMS Health SVP Murray Aitken as saying at the Reuters Health Summit that generics also would increase their dominance in terms of prescriptions dispensed, increasing from 77% during the first half of this year to perhaps 85% by 2014.



Anumber of blockbuster drugs are expected to lose patent protection and face generic competition in the years to come, notably Pfizer’s cholesterol drug Lipitor (atorvastatin calcium) –– the world’s top-selling drug, with more than $7 billion in sales in the United States alone, according to IMS –– which will lose protection next year and face generic competition from Ranbaxy Labs.


Login or Register to post a comment.